These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Schrijver LH, Antoniou AC, Olsson H, Mooij TM, Roos-Blom MJ, Azarang L, Adlard J, Ahmed M, Barrowdale D, Davidson R, Donaldson A, Eeles R, Evans DG, Frost D, Henderson A, Izatt L, Ong KR, Bonadona V, Coupier I, Faivre L, Fricker JP, Gesta P, van Engelen K, Jager A, Menko FH, Mourits MJE, Singer CF, Tan YY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes AM, Caldes T, Simard J, Olah E, Jakubowska A, Rantala J, Osorio A, Hopper JL, Phillips KA, Milne RL, Beth Terry M, Noguès C, Engel C, Kast K, Goldgar DE, van Leeuwen FE, Easton DF, Andrieu N, Rookus MA, Epidemiological Study of Familial Breast Cancer, Gene Etude Prospective Sein Ovaire Sein, Hereditary Breast and Ovarian Cancer Research Group Netherlands, and International BRCA1/2 Carrier Cohort Study. Am J Obstet Gynecol; 2021 Jul; 225(1):51.e1-51.e17. PubMed ID: 33493488 [Abstract] [Full Text] [Related]
7. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, Andrulis IL, West DW, Li FP, Southey MC, Giles GG, McCredie MR, Hopper JL, Whittemore AS. Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):350-6. PubMed ID: 15734957 [Abstract] [Full Text] [Related]
8. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, Lynch CF, Bertelsen L, Capanu M, Concannon P, Borg A, Børresen-Dale AL, Diep A, Teraoka S, Torngren T, Xue S, Bernstein JL. Breast Cancer Res Treat; 2010 Feb; 120(1):175-83. PubMed ID: 19597986 [Abstract] [Full Text] [Related]
9. Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). Lecarpentier J, Noguès C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker JP, Caron O, Stoppa-Lyonnet D, Berthet P, Faivre L, Bonadona V, Buecher B, Coupier I, Gladieff L, Gesta P, Eisinger F, Frénay M, Luporsi E, Lortholary A, Colas C, Dugast C, Longy M, Pujol P, Tinat J, GENEPSO, Lidereau R, Andrieu N. Breast Cancer Res; 2012 Jul 03; 14(4):R99. PubMed ID: 22762150 [Abstract] [Full Text] [Related]
11. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. Bernholtz S, Laitman Y, Kaufman B, Paluch Shimon S, Friedman E. Breast Cancer Res Treat; 2011 Sep 03; 129(2):557-63. PubMed ID: 21499684 [Abstract] [Full Text] [Related]
18. Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, Klijn J, Armel S, Foulkes WD, Tung N, Moller P, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group. Breast Cancer Res Treat; 2009 Mar 01; 114(1):127-35. PubMed ID: 18483851 [Abstract] [Full Text] [Related]